| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
pTH (1-44) (human) targets the parathyroid hormone 1 receptor (PTH1R), a class B G-protein coupled receptor. By binding to PTH1R, it activates signaling cascades including the Gs/cAMP/PKA pathway and the Gq/PLC pathway. It plays a crucial role in calcium homeostasis and bone metabolism.
|
|---|---|
| ln Vitro |
In vitro, pTH (1-44) (human) acts as a fragment of human parathyroid hormone that targets the PTH receptor. It is used in cell-based assays to study PTH receptor signaling, bone metabolism, and calcium homeostasis. Activation of PTH1R leads to downstream signaling that modulates gene expression related to bone formation and calcium regulation.
|
| ln Vivo |
Specific in vivo activity data for pTH (1-44) (human) is not detailed in the provided sources. As a PTH receptor agonist, it plays a crucial role in calcium and phosphate metabolism. It is a key tool for studying bone metabolism and calcium homeostasis.
|
| Enzyme Assay |
In vitro receptor binding assays for pTH (1-44) (human) typically involve measuring its affinity for the PTH1R receptor. The peptide is incubated with cells expressing the receptor, and binding is quantified. Functional assays, such as measuring cAMP production upon receptor activation, are also used to confirm its agonistic activity.
|
| Cell Assay |
Cell culture protocols for pTH (1-44) (human) involve treating bone-derived cells with the peptide at varying concentrations. The effects on cell signaling (e.g., cAMP, PKA, CREB) and gene expression are then assessed. The peptide is dissolved in a suitable solvent and added to the culture medium.
|
| Animal Protocol |
In vivo animal study protocols for pTH (1-44) (human) would be similar to those for other PTH fragments. Typically, it would be administered to animal models to study its effects on bone metabolism and calcium homeostasis. Dosing regimens and endpoints would depend on the specific research question.
|
| ADME/Pharmacokinetics |
pTH (1-44) (human) has a molecular weight of 5063.86 g/mol, a formula of C225H366N68O61S2, and a CAS number of 85568-24-7. It is typically stored as a powder at -20°C. The peptide is soluble in aqueous solutions and is available with high purity.
|
| Toxicity/Toxicokinetics |
Toxicological data for pTH (1-44) (human) is not extensively reported, as it is a research peptide. Standard laboratory safety precautions should be followed. No specific toxicity studies are mentioned in the provided sources. It is not intended for human therapeutic use.
|
| Additional Infomation |
pTH (1-44) (human) has a CAS number of 85568-24-7. It is a fragment of human parathyroid hormone (pTH) and plays a crucial role in calcium homeostasis and bone metabolism. It is not approved for therapeutic use.
|
| Molecular Formula |
C225H366N68O61S2
|
|---|---|
| CAS # |
85568-24-7
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
